Alentis Therapeutics is a clinical-stage biotech startup investigating novel therapeutics for organ fibrosis and CLDN1-positive malignancies. Alentis announced $105 million in Series C funding today. The round was led by Jeito Capital, Novo Holdings A/S, and RA Capital Management, with previous investors including BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund, and Schroders Capital participating.
Alentis has made significant progress since its $67 million Series B funding in June 2021: the ALE.F02 MAD study is nearing completion it has clearly defined the CLDN1+ cancer patient population, including T-cell excluded cancers, to develop ALE.C04 in oncology; it has established the platform to engineer CLDN1 antibody drug conjugates and bi-specific antibodies, which the Series C will help to further develop; and it is expanding its team of top talent.
The CLDN1 firm, Alentis Therapeutics, is a clinical-stage biotechnology company focused on finding novel therapeutics for CLDN1+ malignancies and organ fibrosis.
Alentis is pioneering a novel method to altering and reversing disease development by targeting CLDN1, a hitherto unexplored target that is important in the pathogenesis of malignancies with immune evasive qualities and fibrotic illness across several organs.
Alentis is the sole business working on CLDN1-targeted therapies for solid tumors and fibrosis. The company was created in 2019 on the basis of groundbreaking research conducted in Prof. Thomas Baumert MD’s laboratory at the University of Strasbourg and the French National Institute of Health.
Alentis is located in Switzerland’s pharma-biotech centre of Basel, with a research and development subsidiary in Strasbourg, France.
